New Delhi, Aug 25: Scientists in India have developed a novel smartphone-enabled platform utilizing a fluorescence-responsive molecule that significantly simplifies and enhances the accessibility of diagnosing Alzheimer’s disease (AD). The technology offers a cost-effective and user-friendly approach to detect amyloid-β (Aβ), a key biomarker for the neurodegenerative disorder.
Information was available with The Chenab Times detailing how the newly developed tiny molecule, named TZ-48, undergoes fluorescence changes upon interacting with Aβ. These alterations in fluorescence intensity are then captured and quantified using a dedicated smartphone application, enabling rapid and straightforward detection of the biomarker. This innovation holds considerable potential for widespread screening and staging of Alzheimer’s disease.
Alzheimer’s disease is a progressive neurological condition characterized by a decline in memory, cognitive functions, and behavioral changes. The underlying pathology involves the misfolding and aggregation of amyloid-β proteins, which form plaques in the brain, leading to synaptic dysfunction and neurodegeneration.
Current diagnostic frameworks, such as the National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines, identify Aβ, tau, and neurodegeneration as core biomarkers. Aβ pathology, being an early and specific indicator of AD, is considered a reliable diagnostic marker. While advanced imaging techniques like positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable insights, their high cost, requirement for specialized infrastructure, and need for expert personnel limit their widespread application. Similarly, blood-based assays for Aβ and tau, though promising, are often expensive and complex, underscoring the critical need for simpler, more scalable diagnostic tools.
Fluorescence lifetime imaging microscopy (FLIM) has emerged as a powerful sensing method due to its robustness against probe concentration variations and photobleaching, which enhances the precision of biomarker detection.
Researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institute under the Department of Science and Technology, have engineered a smart fluorescence lifetime-responsive probe. This probe demonstrates high selectivity, sensitivity, and differential detection capabilities for Aβ fibrils (Aβf) through turn-on fluorescence and distinct lifetime signatures.
The molecule, TZ-48, has been detailed in the journal ACS Chemical Neuroscience. It exhibits excellent blood-brain barrier permeability and robustly labels Aβ plaques in the brains of transgenic AD mouse models. Its compatibility with confocal laser scanning microscopy (CLSM) and FLIM allows for quantitative mapping of Aβ burden across different stages of the disease. Furthermore, TZ-48 has shown efficacy in sensitive detection of Aβ in cerebrospinal fluid (CSF) and blood serum, enabling accurate differentiation between AD-affected and healthy mice.
To facilitate clinical translation, a team of scientists, including Krithi K. Bhagavath, Madhu Ramesh, Yogendra Kumar, Sabyasachi Mandal, Hiriyakkanavar Ila, and Thimmaiah Govindaraju, developed ADxFluor. This platform integrates the fluorescence response of TZ-48 with smartphone technology for rapid and unbiased quantification of serum Aβ levels.
The combined system offers dual-mode brain imaging capabilities, biofluid detection, and smartphone-based quantification of Aβ in biological fluids. This integration positions ADxFluor as a foundational technology for developing next-generation smart diagnostic systems for Alzheimer’s and other neurodegenerative diseases. The deployment of TZ-48 with the ADxFluor platform establishes a portable, low-cost, and user-friendly point-of-care diagnostic solution, marking a significant advancement in AD diagnostics.
❤️ Support Independent Journalism
Your contribution keeps our reporting free, fearless, and accessible to everyone.
Or make a one-time donation
Secure via Razorpay • 12 monthly payments • Cancel anytime before next cycle
(We don't allow anyone to copy content. For Copyright or Use of Content related questions, visit here.)
The Chenab Times News Desk
